Evidence map›Paper›PMID 37082886›Full record

ArticleCancer science2023

Association of frequent hypermethylation with high grade histological subtype in lung adenocarcinoma.

Yuki Ito, Genki Usui, Motoaki Seki, Masaki Fukuyo, Keisuke Matsusaka, Takayuki Hoshii, Yuki Sata, Junichi Morimoto, Atsushi Hata, Takahiro Nakajima and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Yuki ItoDepartment of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Genki UsuiDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Motoaki SekiDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.ORCID https://orcid.org/0000-0003-4207-1408
Masaki FukuyoDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Keisuke MatsusakaDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takayuki HoshiiDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yuki SataDepartment of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Junichi MorimotoDepartment of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Atsushi HataDepartment of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takahiro NakajimaDepartment of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Bahityar RahmutullaDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Taisuke KaihoDepartment of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Terunaga InageDepartment of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.ORCID https://orcid.org/0000-0001-5585-1601
Kazuhisa TanakaDepartment of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yuichi SakairiDepartment of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hidemi SuzukiDepartment of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ichiro YoshinoDepartment of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Atsushi KanedaDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.ORCID https://orcid.org/0000-0002-6980-5515
Chiba University · JP

Funding

Chiba University Global Prominent Research grant 2018-Y9Chiba University IAAR Research Support ProgramJapan Agency for Medical Research and Development Practical Research for Innovative Cancer Control 19ck0106263h0003
6 · The paper itself

Abstract

Lung adenocarcinoma is classified morphologically into five histological subtypes according to the WHO classification. While each histological subtype correlates with a distinct prognosis, the molecular basis has not been fully elucidated. Here we conducted DNA methylation analysis of 30 lung adenocarcinoma cases annotated with the predominant histological subtypes and three normal lung cases using the Infinium BeadChip. Unsupervised hierarchical clustering analysis revealed three subgroups with different methylation levels: high-, intermediate-, and low-methylation epigenotypes (HME, IME, and LME). Micropapillary pattern (MPP)-predominant cases and those with MPP components were significantly enriched in HME (p = 0.02 and p = 0.03, respectively). HME cases showed a significantly poor prognosis for recurrence-free survival (p < 0.001) and overall survival (p = 0.006). We identified 365 HME marker genes specifically hypermethylated in HME cases with enrichment of "cell morphogenesis" related genes; 305 IME marker genes hypermethylated in HME and IME, but not in LME, with enrichment "embryonic organ morphogenesis"-related genes; 257 Common marker genes hypermethylated commonly in all cancer cases, with enrichment of "regionalization"-related genes. We extracted surrogate markers for each epigenotype and designed pyrosequencing primers for five HME markers (TCERG1L, CXCL12, FAM181B, HOXA11, GAD2), three IME markers (TBX18, ZNF154, NWD2) and three Common markers (SCT, GJD2, BARHL2). DNA methylation profiling using Infinium data was validated by pyrosequencing, and HME cases defined by pyrosequencing results also showed the worse recurrence-free survival. In conclusion, lung adenocarcinomas are stratified into subtypes with distinct DNA methylation levels, and the high-methylation subtype correlated with MPP-predominant cases and those with MPP components and showed a poor prognosis.

Indexed as

Adenocarcinoma of LungLung NeoplasmsBiomarkersDNA MethylationHumansKruppel-Like Transcription FactorsNeoplasm StagingPrognosisBiomarkersKruppel-Like Transcription FactorsZNF154 protein, humanDNA methylationhigh-grade subtypehistological subtypelung adenocarcinomamicropapillary component

Identifiers

PMID37082886
PMCPMC10323093
OpenAlexW4366603440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.